Scientific research is constantly evolving and so is the continuously expanding data on BenchSci’s application. That’s why we recently partnered with Mary Ann Liebert, Inc. publishers to continue enabling scientific discoveries and medical breakthroughs by making their data available on BenchSci’s AI-Assisted Reagent Selection application. This partnership is an exciting one for many reasons, particularly because it diversifies and enriches the already vast data accessible to our users. 

Adding even more open- and closed-access data means additional assurance that you are selecting the right reagents, thereby greatly facilitating experimental planning, proposals, and projects in both academia and industry sectors. Mary Ann Liebert, Inc.’s collection in particular adds some unique perspectives in biotech and biomedical research in addition to data from their 100+ journals to the over 14 million papers already available on our application.

Mary Ann Liebert, Inc. was founded to promote biotech discoveries

Mary Ann Liebert Inc.’s origin story stands out in the male-dominated world of science publishing.1,2 The publishing house was founded in 1980 by Mary Ann Liebert,1 an experienced medical and biotech research journalist. After her father was diagnosed with Parkinson’s Disease, Liebert sought to learn and raise awareness about Parkinson’s cutting-edge research taking place behind the scenes – what she called at the time “the news behind the news.” 1 

Knowing that scientists were tirelessly working to ensure that breakthroughs reached the clinic faster gave her hope that one day people like her late father would be able to live better lives despite PD or other chronic illnesses. Harnessing this dream, ultimately led her to found Mary Ann Liebert, Inc.1-3 To date, Mary Ann Liebert, Inc. publishers have reached many remarkable milestones, including being the first to report on acquired immunodeficiency syndrome before it was declared an epidemic in the US1 and dominating the biotech trade magazine sector worldwide with their flagship publication Genetic Engineering News (Gen Eng).1-3 

Mary Ann Liebert Publications that are Leading Contributors to the Biotech and Biomedical Fields

Like Gen Eng, many of Mary Ann Liebert’s publications began as pioneers in their respective fields. Below, some of these publications are highlighted to showcase the value they bring to scientists using our Reagent Selection application.

Journal of Neurotrauma

First published in 1984, the Journal of Neurotrauma has established itself as a leader in the field of traumatic brain and spinal cord injury. As the official journal of the National Neurotrauma Society, and International Neurotrauma Society, the peer-reviewed publication reports on a wide range of data from basic science studies on the biology of trauma to clinical investigations for patient care. Its authoritative stem cell biology and transplantation content has been one of the reasons the journal consistently receives reputable impact factors,5 which denote its authority in the field. With more specialized treatments like gene therapy being considered for the brain, the data from this journal will surely prove to be an asset to users of BenchSci’s Reagent Selection application. Users will be able to benefit from this journal’s data when,

  • researching neurobiological molecular and cellular mechanisms, 
  • setting up experiments, projects, and /or proposals for drug targets, and when,
  • looking for specialized animal models and cell models that truly reflect the brain’s architecture, including the blood-brain barrier, critical to consider in drug delivery.

Human Gene Therapy

Established in 1990, Human Gene Therapy was the first peer-reviewed journal in the field of human gene therapy. At the time, the publication gained additional trust in the biotech scientific community when the “Father of Gene Therapy” William French Anderson became its editor-in-chief.1 The publication remained the main source for gene therapy reports for many years until other great publications such as Molecular Therapy, which was first printed a decade after Human Gene Therapy, became available.2 

Presently, Dr. Terence R. Flotte, another internationally-recognized pioneer in the field of human gene therapy, and the first to employ adeno-associated virus (AAV) vector for gene therapy serves as the editor-in-chief.6 Human Gene Therapy is also the official journal of the European Society for Gene and Cell Therapy.7 The editorial’s team knowledge of virus vectors has served to ensure scientists rely on Human Gene Therapy for its insightful reports on vectored immunoprophylaxis, and valuable preclinical, and translational data on AAV’s use in cancer immunotherapy, and gene therapy. 

Scientists using BenchSci's Reagent Selection application to search for enzymatic reagents for viral vector design, cellular and/or animal models for vectored immunoprophylaxis, gene therapy, or oncolytic therapy, and/or antibodies or other reagents to identify specific viral vectors or targets will benefit data from both open and access articles within this prestigious journal.

Nucleic Acid Therapeutics

Focusing solely on the clinical aspect and therapeutic advances of manipulating nucleic acids, Nucleic Acid Therapeutics first went to print in 1991. Nucleic Acid Therapeutics targeted an overlooked field not quite covered by dominating journals at the time. Established in 1974, the high impact factor Nucleic Acids Research focuses on mechanistic and structural reports on nucleic acids. Aside from publishing data relevant to therapeutic applications and drug development, the journal also reports on cutting-edge basic research on nucleic acids and related compounds – oligonucleotides, gene modifiers, aptamers, RNA nanoparticles, ribozymes, and others – used in gene expression work. 

Scientists can now leverage additional data on siRNA, shRNA, and miRNA on the Reagent Selection application. Recently, BenchSci included off-binding data information for siRNA and shRNA, and this update will complement the data from Nucleic Acid Therapeutics well for users researching gene silencing or topics involving RNAi. Other notable recent add-ons include the addition of third-party gene expression data critical for target validation and other experiments centered on cell products.

Diabetes Technology & Therapeutics

For more than twenty years, Diabetes Technology & Therapeutics remains the main peer-reviewed journal for pharmaceutical and medical reports in the field of sugar- and insulin-related metabolic diseases. With pertinent reports on drug development and drug delivery systems, the journal has established itself as a staple in diabetes research. Interestingly, as COVID-19 researchers have reported a definitive link to insulin and sugar regulation, the journal’s data is rather topical today in many fields including virology, chronic illnesses, and cancer.

Industry and academia scientists performing preclinical, clinical, and translational research will benefit from finding the latest closed-access data on diabetes, including data on hormones for artificial pancreas research on BenchSci’s Reagent Selection application. Of note, hormones have also been shown to play a significant role in developing both acute and chronic COVID-19. Diabetes Technology & Therapeutics’ data will prove beneficial to many users helping to inform projects, proposals, and grants for metabolism and COVID-19 research.

The CRISPR Journal

Enlisting the founding editor of Nature Genetics, Dr. Kevin Davies,8 Mary Ann Liebert publishers launched The CRISPR Journal in 2018. Another pioneering publication, the CRISPR Journal, remains a go-to source for peer-reviewed gene editing research addressing questions from a diverse range of fields such as cell biology, genetics and genomics, immunology, infectious diseases, microbiology, molecular biology, neuroscience, plant biology, and others. Catering to both the biotech and pharma industries, and applied academic research, the journal has attained a reputable impact factor of 4.321 in just four years since being established, which highlights its relevance to its target audience. For comparison, Nature’s Scientific Reports’ impact factor is 4.996.

Being at the forefront of reported research on CRISPR will benefit BenchSci’s users as novel gene target searches can be cumbersome through traditional means; thanks to additional data from The CRISPR Journal, the chance of finding guide RNAs for novel targets is higher. The data will also prove useful for scientists searching for CRISPR reagents on BenchSci’s application  to inform their gene editing experiments and be a complement to the aforementioned off-binding data update for RNA-based reagents. The journal’s data coupled with this latest update will better enable research progress for BenchSci’s users.

BenchSci’s Partnership with Mary Ann Liebert Will Equip Scientists with the Right Tools and Set them up for Success

Mary Ann Liebert publishers have cemented their role as leaders in biotech breakthroughs for over forty years. Liebert’s forward thinking continues to be the driving force guiding the publishing house as exemplified in their Big Data journal’s most recent issue which delved into a potential framework for equitable public data acquisition, analysis, and visualization.9 Most importantly, the addition of Mary Ann Liebert’s authoritative data will ensure BenchSci’s users gain an edge in their research undertakings enabling project continuation, and tomorrow’s breakthroughs.

Search BenchSci’s Reagent Selection application now to see the data in action. 


References

  1. Emily McElroy (Column Editor, Kubilius is Collection Development/Special Projects Librarian) (2003) An Interview with Mary Ann Liebert and Tom Mulak, Serials Review, 29:2, 137-143, DOI: 10.1080/00987913.2003.10764811

  2. Mary Ann Liebert Publishers. (2013) An Interview with Mary Ann Liebert, Publisher of Stem Cells and Development. Stem Cells Dev 22(Suppl 1): 2–3. DOI: 10.1089/scd.2013.1503

  3. Mary Ann Liebert Publishers. (2022). A Letter from Mary Ann. Liebertpub.com. Accessed October, 2022. https://home.liebertpub.com/company/company-home/153

  4. CEOViews. (2022). Top 12 Biotech Magazines and Blogs to Follow. Accessed October, 2022. https://theceoviews.com/top-12-biotech-magazines-and-blogs-to-follow/

  5. Mary Ann Liebert Publishers (2020). Historic Impact Factors for Mary Ann Liebert, Inc. Journals. Accessed October, 2022. https://home.liebertpub.com/news/historic-impact-factors-for-mary-ann-liebert-inc-journals/3729

  6. University of Massachusetts Medical School: Office of the Chancellor Michael F. Collins, MD, FACP. (2022). Terence R. Flotte, MD. Accessed October, 2022.  https://www.umassmed.edu/chancellor/senior-leadership/organization-chart/terence-r-flotte-md/

  7. European Society for Gene and Cell Therapy. (2022). Our Partner Journal. Accessed October, 2022. https://www.esgct.eu/Membership/Human-Gene-Therapy.aspx

  8. Mary Ann Liebert Publishers (2017). The CRISPR Journal, a New Peer-Reviewed Journal on Gene Editing Technology and Applications, Launching in 2018. News Release. Accessed October, 2022. https://home.liebertpub.com/news/the-crispr-journal-a-new-peer-reviewed-journal-on-gene-editing-technology-and-applications-launching-in-2018/2177

  9. Mary Ann Liebert Publishers. (2022). Building an Equity-Centered Public Health Data System. News Release. Accessed October, 2022. https://home.liebertpub.com/news/the-crispr-journal-a-new-peer-reviewed-journal-on-gene-editing-technology-and-applications-launching-in-2018/2177

  10. Mary Ann Liebert Publishers (2020). Increasing Diversity and Community Participation in Environmental Engineering. Lab Manager: News. Accessed October, 2022. https://www.labmanager.com/news/increasing-diversity-and-community-participation-in-environmental-engineering-24471